Purpose Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid leukemia (AML) may predict outcome. However, the optimal time points for investigation, the best antibody ...
Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML). A new review ...
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial Invivoscribe Inc., a ...
CARLSBAD, Calif., March 15, 2024 /PRNewswire/ -- Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical ...
SAN DIEGO--(BUSINESS WIRE)--Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest ...
New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...
Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback